INT275861

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.17
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 4
Disease Relevance 3.45
Pain Relevance 1.95

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (PES1) nucleoplasm (PES1) nucleolus (PES1)
nucleus (PES1) intracellular (PES1)
Anatomy Link Frequency
fat 2
PES1 (Homo sapiens)
Pain Link Frequency Relevance Heat
fibrosis 36 99.14 Very High Very High Very High
Chronic pancreatitis 220 98.88 Very High Very High Very High
Bile 36 93.00 High High
Pain 80 92.32 High High
Bioavailability 4 83.84 Quite High
Potency 4 75.36 Quite High
Cholecystokinin 28 59.44 Quite High
Inflammation 8 58.32 Quite High
nud 4 57.20 Quite High
alcohol 16 22.00 Low Low
Disease Link Frequency Relevance Heat
Weight Gain 4 99.68 Very High Very High Very High
Cystic Fibrosis 36 99.14 Very High Very High Very High
Pancreatitis 220 98.88 Very High Very High Very High
Steatorrhea 68 98.60 Very High Very High Very High
Appetite Loss 36 97.40 Very High Very High Very High
Pain 76 92.32 High High
Weight Loss 4 90.48 High High
Irritable Bowel Syndrome /

Irritable Bowel Syndrome Super

4 83.24 Quite High
Intestinal Obstruction 4 82.64 Quite High
Disease 20 79.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Randomized placebo controlled trials have shown that treatment with PES improves steatorrhea, as measured by increased fat absorption, reduced fecal fat excretion, decreased stool weight and frequency, improved stool consistency and improved symptom scores.15–18 Other studies have demonstrated that patients receiving PES report weight gain and improved quality of life, and studies demonstrate decreased defecation rates,19 increased cholesterol absorption and improved enterohepatic cycling of bile salts.5,20

Pain

PES Binding (receiving) of in fat associated with pain, bile, steatorrhea and weight gain
1) Confidence 0.17 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710383 Disease Relevance 1.44 Pain Relevance 1.01
PES should be initiated in patients suffering from CP and steatorrhea.
PES Binding (initiated) of associated with steatorrhea and chronic pancreatitis
2) Confidence 0.17 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710383 Disease Relevance 0.70 Pain Relevance 0.31
Improvement in gallbladder contraction with PES has been demonstrated in some studies36,37 but not in others.7

Malnutrition

PES Binding (contraction) of associated with appetite loss
3) Confidence 0.17 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710383 Disease Relevance 1.05 Pain Relevance 0.50
Unfortunately, therapeutic failures (gastrointestinal symptoms and fat malabsorption) have been noted in patients with CF after pharmacists substituted a preferred brand of PES with generic pancrelipase, which rapidly resolved after initial therapy was reinstituted.105
PES Binding (brand) of in fat associated with fibrosis
4) Confidence 0.17 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710383 Disease Relevance 0.19 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox